Published in Obstet Gynecol on October 01, 1997
Testing the robustness of the likelihood-ratio test in a variance-component quantitative-trait loci-mapping procedure. Am J Hum Genet (1999) 4.54
Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol (2013) 1.33
Immune thrombocytopenia in pregnancy. Hematol Oncol Clin North Am (2009) 0.94
Clinical aspects of pregnancy and delivery in patients with chronic idiopathic thrombocytopenic purpura (ITP). Korean J Intern Med (2005) 0.83
Can we predict neonatal thrombocytopenia in offspring of women with idiopathic thrombocytopenic purpura? Blood Res (2014) 0.81
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood (1996) 7.31
Images in clinical medicine. Heparin-induced skin necrosis. N Engl J Med (1996) 3.30
CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem (1991) 2.82
Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Engl J Med (1990) 2.43
Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1986) 2.31
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost (2011) 2.11
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med (1986) 2.01
Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynaecol (1990) 2.00
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke (1993) 1.54
Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol (2000) 1.52
Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol (1992) 1.49
Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. J Thromb Haemost (2012) 1.47
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
Lactic acidosis and renal enlargement at diagnosis and relapse of acute lymphoblastic leukemia. J Pediatr (1994) 1.43
The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol (1984) 1.43
[Withdrawing the use of acetylsalicyclic acid prior to an operation usually not necessary]. Ned Tijdschr Geneeskd (2003) 1.42
How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis (2001) 1.41
Thrombocytopenia with absent radii: frequency of marrow megakaryocyte progenitors, proliferative characteristics, and megakaryocyte growth and development factor responsiveness. Pediatr Hematol Oncol (2000) 1.40
Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood (1994) 1.39
Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol (1984) 1.36
Sequential regulation of the small GTPase Rap1 in human platelets. Mol Cell Biol (2000) 1.32
Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood (1983) 1.32
Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation (2003) 1.28
The origin of P-selectin as a circulating plasma protein. Thromb Haemost (1997) 1.25
Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood (1994) 1.21
Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am J Hum Genet (1998) 1.20
Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood (1986) 1.20
Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost (1991) 1.19
Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood (1987) 1.18
Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood (1997) 1.14
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) Eur Heart J (1996) 1.12
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke (1997) 1.11
T cell antigen receptors in autoimmunity. J Immunol (1988) 1.11
Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang (1987) 1.09
Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. J Pediatr (1983) 1.09
Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin. J Pediatr (1985) 1.07
Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost (1996) 1.03
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol (2001) 1.02
Conformational changes in aspartate transcarbamylase. 3. A functional model for allosteric behavior. J Biol Chem (1971) 1.01
Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood (1997) 0.98
Responses of platelets to strains of streptococcus sanguis: findings in healthy subjects, Bernard-Soulier, Glanzmann's, and collagen-unresponsive patients. Thromb Haemost (1987) 0.97
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation (1993) 0.97
Absence of ligands bound to glycoprotein IIB-IIIA on the exposed surface of a thrombus may limit thrombus growth in flowing blood. J Clin Invest (1994) 0.96
Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematology Am Soc Hematol Educ Program (2001) 0.94
Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling. Arterioscler Thromb Vasc Biol (1999) 0.94
Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol (1995) 0.93
Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VIII inhibitor. Eur J Haematol (1997) 0.92
The usefulness of five D-dimer assays in the exclusion of deep venous thrombosis. J Thromb Haemost (2003) 0.92
Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Semin Hematol (1998) 0.92
Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol (1993) 0.91
Prenatal diagnosis of neonatal alloimmune thrombocytopenia using allele-specific oligonucleotide probes. Blood (1991) 0.91
The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost (2001) 0.90
Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood (1995) 0.90
Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut (1990) 0.89
Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Preliminary report. Am J Dis Child (1989) 0.89
Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees. Leukemia (2012) 0.89
Platelet adhesion to collagen. Thromb Haemost (1995) 0.89
Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost (1996) 0.88
Th1 and Th2 cytokines in a patient with Evans' syndrome and profound lymphopenia. Br J Haematol (2000) 0.88
Biochemical and immunohistochemical characteristics of CD62 and CD63 monoclonal antibodies. Expression of GMP-140 and LIMP-CD63 (CD63 antigen) in human lymphoid tissues. Virchows Arch B Cell Pathol Incl Mol Pathol (1991) 0.88
A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol (1992) 0.88
Biochemical characterization of PECAM-1 (CD31 antigen) on human platelets. Thromb Haemost (1991) 0.88
Antiplatelet antibody testing in thrombocytopenic pregnant women. Am J Obstet Gynecol (1996) 0.87
Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. Science (1987) 0.86
A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood (1993) 0.86
Thrombocytopenia and the neglected megakaryocyte. N Engl J Med (1992) 0.86
Molecular analysis of the genotype-phenotype relationship in factor X deficiency. Hum Genet (2000) 0.86
The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis. Semin Hematol (2000) 0.84
Idiopathic immune thrombocytopenic purpura: an update. Semin Hematol (2000) 0.84
A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia. Am J Hematol (1984) 0.84
Fetal and neonatal thrombocytopenia. Blood Rev (1995) 0.84
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation (1989) 0.83
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol (2001) 0.83
MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol (1994) 0.83
Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes (1995) 0.83
Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis (2004) 0.82
Intravenous usage of gammaglobulin: humoral immunodeficiency, immune thrombocytopenic purpura, and newer indications. Cancer Invest (1985) 0.82
Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang (1986) 0.82
Platelet adhesion to cyanogen-bromide fragments of collagen alpha 1(I) under flow conditions. Blood (1993) 0.82
Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol (2001) 0.82
Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion (1990) 0.82
Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost (1994) 0.82
Cytomegalovirus infection causes delayed platelet recovery after bone marrow transplantation. Blood (1991) 0.81
Platelet adhesion to collagen and endothelial cell matrix under flow conditions is not dependent on platelet glycoprotein IV. Blood (1994) 0.81
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant (1999) 0.81
Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant (1998) 0.81
6th International Immunoglobulin Symposium: poster presentations. Clin Exp Immunol (2009) 0.81
T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol (2003) 0.81
Platelet adhesion to collagen type IV under flow conditions. Blood (1996) 0.81
ATP-ADP compartmentation in storage pool deficient platelets: correlation between granule-bound ADP and the bleeding time. Br J Haematol (1983) 0.80
Total knee arthroplasty in hemophilia. J Bone Joint Surg Am (1985) 0.80
Autoimmune neutropenia of childhood. Crit Rev Oncol Hematol (1987) 0.80
Modulation of mononuclear phagocyte system function and circulating immune complexes by lyophilized concentrates in patients with classic hemophilia. Clin Immunol Immunopathol (1984) 0.80
Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol (1997) 0.80
Immune thrombocytopenia in pregnancy: autoimmune and alloimmune. J Reprod Immunol (1997) 0.80